Fujifilm Toyama Chemical Co. has announced a pause in enrollment, as of the end of March, in the currently ongoing phase III clinical trial in Japan concerning its anti-influenza drug Avigan Tablet (favipiravir), targeting patients infected with novel coronavirus infections (COVID-19).
Fujifil Corporation has announced the transfer of the radiopharmaceutical business of Fujifilm Toyama Chemical, a consolidated subsidiary of Fujifilm, to PeptiDream Inc.
FUJIFILM Toyama Chemical has announced the initiation of a new phase III clinical trial in Japan concerning its anti-influenza drug Avigan® Tablet (favipiravir), targeting patients infected with novel coronavirus infections (COVID-19).
Yesterday, Genentech, Inc. filed a complaint in the Eastern District of Texas alleging that Centus Biotherapeutics, Ltd., Fujifilm Kyowa Kirin Biologics Co., Ltd., Fujifilm Corp., and Kyowa Kirin Co, Ltd. (collectively, Centus) proposed biosimilar to Genentech’s AVASTIN (bevacizumab) product infringes 10 U.S. patents. Genentech’s complaint, styled as a Complaint for Patent Infringement and Declaratory Judgment, names four foreign defendants and no U.S. entities. Because all named defendants are foreign corporations, Genentech alleges that venue is proper in any judicial district and that personal jurisdiction is proper in Texas because the product will be sold in Texas.
TOKYO (Reuters) - Fujifilm Holdings Corp said on Friday it was seeking approval for its flu drug Avigan as a treatment for COVID-19 in Japan, a move that comes after a late-stage study showed reduced recovery time for patients with non-severe symptoms.
TOKYO, October 16, 2020 — FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced that the company filed an Application for Partial Changes to manufacturing and marketing approval matters of its anti-influenza drug Avigan® Tablet (generic name: favipiravir,“Avigan”) to the Ministry of Health, Labour and Welfare in Japan. The filing seeks to add an indication and other items relating to novel coronavirus infections (hereinafter “COVID-19”).
The government is planning to fast-track the approval of anti-viral drug Avigan as a COVID-19 treatment in November even before its developer has filed for a regulatory review, government sources said Saturday.
Indian generic drug maker Dr Reddy's Laboratories on Wednesday announced the launch of antiviral drug Avigan (favipiravir) tablets, currently being manufactured by Japanese drug giant Fujifilm Toyama Chemical Co, for potential treatment of mild to moderate Covid-19.
Prime Minister Shinzo Abe said on May 15 that the government will not necessarily require Fujifilm Toyama Chemical to submit its clinical trial results for the review of its antiviral Avigan (favipiravir) for the treatment of novel coronavirus disease as…
Shares of Hikal were locked in the upper circuit band of 5 per cent at Rs 115 on the BSE on Friday after the company announced the successful development of Favipiravir active pharmaceutical ingredient (API) and its intermediates. The drug is in various stages of clinical trials in many countries as an experimental treatment of Covid-19.